REBEL Bare Metal Stent Data

Not every patient is a candidate for drug-eluting stents. For those who need a bare-metal option, the REBEL Stent is a clear choice. The Platinum Chromium (PtCr) BMS in the OMEGA Trial had only 7.4% Target Lesion Revascularization (TLR).


  • A prospective, single-arm, multi-center trial
  • De novo lesions ≤ 28 mm in length and ≥ 2.25 mm to ≤ 4.50 mm in diameter
  • Primary endpoint: TLF at 9 months
  • Analysis: Primary endpoint based on pre-defined performance goal of 21.2%

Bare-Metal Stent Data - In Perspective

Results from different clinical trials are not directly comparable. Information provided here for educational purposes only.